A practical guide for providers to help patients access Repatha (evolocumab). Covers specialty pharmacy navigation, prior authorization tips, and practice workflow strategies.
You've made the clinical decision that your patient needs Repatha (evolocumab). Now comes the hard part: actually getting it into their hands. For a medication that's been on the market since 2015, the number of patients who still struggle with access is remarkable — and largely preventable with the right workflow.
This guide provides actionable steps your practice can take to reduce the time between prescribing and first injection, minimize prior authorization friction, and keep patients on therapy.
Repatha's supply is stable — Amgen's manufacturing is not the bottleneck. The challenges are:
Most patients expect to fill a new prescription the same day at their local pharmacy. With Repatha, this almost never happens. The specialty pharmacy enrollment process — benefit verification, PA submission, copay card activation, and cold-chain shipping setup — typically takes 3-10 business days for new patients.
Patients who aren't warned about this timeline often interpret the delay as "the pharmacy doesn't have it" or "my doctor didn't send the prescription," leading to frustration and, in some cases, treatment abandonment before they even start.
PA requirements for PCSK9 inhibitors have improved but remain complex. Common reasons for denial include:
Patients who reach the pharmacy without the copay card activated may face a $500+ copay, which causes immediate abandonment. This is entirely preventable.
The Medfinder provider portal allows you to search for pharmacy availability on behalf of your patients. This is especially useful when patients are transitioning between specialty pharmacies or need to find an alternative source quickly. Your staff can search and connect patients with pharmacies that have Repatha available.
Create a standardized process that kicks in every time you prescribe Repatha:
For established patients on Repatha, refill delays are usually caused by late reordering. Advise patients to:
Consider which dosing schedule and device best fit your patient's situation:
Proactive cost counseling at the point of prescribing prevents pharmacy abandonment:
When Repatha access isn't feasible despite best efforts, consider:
Assign a staff member (nurse, medical assistant, or patient coordinator) to manage all PCSK9 inhibitor prescriptions. This person should:
Develop a standardized checklist of documentation needed before submitting PA for Repatha:
Identify 2-3 specialty pharmacies that handle the majority of your PCSK9 inhibitor prescriptions. Having a direct contact at these pharmacies can expedite processing and help resolve issues quickly.
Getting patients their Repatha shouldn't be harder than the clinical decision to prescribe it. The most impactful changes are systemic: building PA submission, copay enrollment, and specialty pharmacy coordination into your prescribing workflow so they happen automatically — not as afterthoughts when the patient calls frustrated a week later.
Key actions:
For the broader clinical context, see our Repatha prescriber briefing for 2026. To share with patients, point them to our patient guide to finding Repatha in stock and Repatha savings guide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
